Patents Examined by Dian C. Jacobson
  • Patent number: 6107072
    Abstract: The present invention discloses a heat-resistant geranylgeranyl diphosphate synthase originating in Thermus thermophilus, along with its production process and its method of use.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: August 22, 2000
    Assignee: Toyota Jidosha Kabushiki Kaisha
    Inventor: Chika Ishida
  • Patent number: 6039944
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 21, 2000
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Patent number: 6020188
    Abstract: A glycoprotein, PECAM-1, and variants thereof can be obtained by expression in a transformed host cell of a polynucleotide coding for the glycoprotein or a variant polypeptide. PECAM-1 can also be isolated from cellular sources. An antibody specific for PECAM-1 or a PECAM variant can be produced via recombinant techniques, or can be obtained from a hybridoma.
    Type: Grant
    Filed: November 16, 1994
    Date of Patent: February 1, 2000
    Assignee: Blood Center Research Foundation
    Inventor: Peter J. Newman
  • Patent number: 6017531
    Abstract: Hydrophillic compositions and methods of use are provided for debriding and wound healing applications. The compositions contain certain proteases produced by microorganisms of the genus Vibrio.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: January 25, 2000
    Assignees: W. R. Grace & Co., Conn. / Teva Pharmaceuticals USA, Inc.
    Inventors: Donald Zane Fortney, Donald Richard Durham, Kang Yang
  • Patent number: 5997864
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: December 7, 1999
    Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Lars C. Petersen, Ulla Hedner, Mirella E. Rasmussen
  • Patent number: 5981704
    Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commercial significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor simulation.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: November 9, 1999
    Assignee: Allelix Biopharmaceutical
    Inventors: Rajender Kamboj, Stephen L. Nutt, Lee Shekter, Michael A. Wosnick
  • Patent number: 5976530
    Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 2, 1999
    Assignees: Chiron Corporation, Hoechst Marion Roussel Deutschland GmbH
    Inventors: Nancy L. Haigwood, Guy Mullenbach, Ernst-Guenter Afting, Eric Paul Paques
  • Patent number: 5972698
    Abstract: The present invention relates to novel inhibitors of human tryptase, to their isolation from leeches, to nucleotide sequences encoding the novel inhibtor molecules or fragments thereof, to vectors containing the coding sequence thereof, to host cells transformed with such vectors, to the recombinant production of the inibitors, to pharmaceutical compositions containing the novel inhibitor molecules, and to their use in diagnosis and therapy.
    Type: Grant
    Filed: January 25, 1996
    Date of Patent: October 26, 1999
    Assignees: Novartis Corporation, UCP Gen-Pharma AG
    Inventors: Hans Fritz, Christian Sommerhoff
  • Patent number: 5972630
    Abstract: A method for determining the presence of an analyte which is a specific binding pair member in a sample suspected of containing the analyte is described. The method involves: bringing together in an aqueous medium, the sample, an enzyme bound to a first specific binding pair member and an inhibitor for the enzyme bound to a second specific binding pair member wherein each specific binding pair member is capable of binding to the analyte or to a specific binding pair member complementary to the analyte; analyzing the medium for the activity of said enzyme; and relating the activity to the amount of analyte present in the medium. Compositions of matter and kits are also described.
    Type: Grant
    Filed: August 19, 1991
    Date of Patent: October 26, 1999
    Assignee: Dade Behring Marburg GmbH
    Inventors: Remy Cromer, Rohan Peries, Dariush Davalian, Carl N. Skold, Edwin F. Ullman, Kesavan Radika
  • Patent number: 5952198
    Abstract: Recombinant Factor VIII expression in a mammalian cell culture can be increased by including a novel liposome-like substance in the culture medium. The liposome-like substance comprises at least two (preferably at least three) different lipids in defined molar ratios. In a preferred embodiment, the addition of a liposome-like substance comprised of dioleoyl phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine in a molar ratio of 4:1:1 to the culture medium of GS-MDR cells resulted in an increase in FVIII production by a factor greater than five.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: September 14, 1999
    Assignee: Bayer Corporation
    Inventor: Sham-Yuen Chan
  • Patent number: 5948759
    Abstract: The present invention relates to peptide of the amino acid sequence of formula (I):82 85 90 Glu Thr His Lys Asp Asp Gln Leu Ile 95 100 Cys Val Asn Glu Asn Gly Gly Cys Glu Gln 105 110 Tyr Cys Ser Asp His Thr Gly Thr Lys Arg 115 120 Ser Cys Arg Cys His Glu Gly Tyr Ser Leu 125 128 Leu Ala Asp Gly Val Ser Cys Thr (SEQ ID NO. 1)and functional equivalents thereof in which amino acids in the above stated sequence are modified or absent and wherein at least one of the cysteine residues may be blocked or replaced and wherein any cysteine residues which remain unblocked or unreplaced may be present in a disulphide bonded state. The invention also includes slats and derivatives of said peptides. The peptides and their salts and derivatives are useful in the treatment of blood clotting disorders.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: September 7, 1999
    Assignee: Nycomed Imaging AS
    Inventors: Mette Husbyn, Peter Fischer, Lars Orning
  • Patent number: 5948889
    Abstract: A method for screening compounds for antimicrobial activity is described that utilizes bacterial protein-protein binding in vitro. The method may be performed using immobilized elements and the immobilization may be carried out using a variety of immobilization means (e.g., columns, beads, adsorbents, nitrocellulose paper, etc.) in order to screen large libraries of compounds.
    Type: Grant
    Filed: May 21, 1996
    Date of Patent: September 7, 1999
    Assignee: Case Western Reserve University
    Inventors: Piet A. J. de Boer, Cynthia A. Hale
  • Patent number: 5945327
    Abstract: An isolated nucleic acid constructs encoding cellulytic enzymes derived from a strain of Bacillus agaradherens, recombinant vectors and host cells comprising such constructs, and methods for obtaining cellulytic enzymes.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: August 31, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Claus Dambmann, Arne Agerlin Olsen, Henrik Bisg.ang.rd-Frantzen, Martin Schulein, Per Linaa Jorgensen, Mads E. Bjoernvad
  • Patent number: 5945328
    Abstract: Trypsin (trypsinogen) may be produced in a filamentous fungus by transforming a filamentous fungus with a vector comprising a DNA sequence encoding protrypsin or a derivative thereof N-terminally fused to a DNA sequence encoding a signal peptide, culturing the transformed filamentous fungus in a suitable culture medium to produce trypsinogen and recovering trypsinogen and/or trypsin from the medium.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: August 31, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Helle Fabricius Woldike, Thomas Borglum Kjeldsen
  • Patent number: 5945403
    Abstract: Fragments of an endothelial cell proliferation inhibitor and method of use therefor are provided. The endothelial proliferation inhibitor is a protein derived from plasminogen, or more specifically is an angiostatin fragment. The angiostatin fragments generally correspond to kringle structures occurring within the endothelial cell proliferation inhibitor. The endothelial cell inhibiting activity of these fragments provides a means for inhibiting angiogenesis of tumors and for treating angiogenic-mediated disease.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: August 31, 1999
    Assignee: The Children's Medical Center Corporation
    Inventors: M. Judah Folkman, Michael S. O'Reilly
  • Patent number: 5935837
    Abstract: The present invention relates xylose isomerases obtainable from strains of Thermotoga. More specifically the invention provides DNA sequences encoding xylose isomerases, expression vectors and host cells comprising the DNA sequences of the invention, and methods of producing xylose isomerases. The invention also provides isolated xylose isomerases free from homologous impurities and obtained by the method of the invention.
    Type: Grant
    Filed: July 28, 1997
    Date of Patent: August 10, 1999
    Assignee: Novo Nordisk A/S
    Inventor: Michael Dolberg Rasmussen
  • Patent number: 5932445
    Abstract: The invention provides signal peptide-containing proteins collectively designated SP, and polynucleotides which identify and encode these molecules. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, treating, and preventing disorders associated with expression of signal peptide-containing proteins.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: August 3, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Janice Au-Young, Roopa Reddy, Lynn E. Murry, Preete Mathur
  • Patent number: 5932433
    Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: August 3, 1999
    Assignee: Affymax Technologies N.V.
    Inventor: Peter J. Schatz
  • Patent number: 5932213
    Abstract: Plasmin precursors are modified so that they exhibit resistance to inhibitors of plasmin. These modified plasmin precursors have fibrinolytic, thrombolytic or antithrombotic properties, which are useful in the treatment of blood clotting diseases or conditions.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: August 3, 1999
    Assignee: British Biotech Pharmaceuticals, Ltd.
    Inventors: Keith Martyn Dawson, Richard James Gilbert
  • Patent number: 5932465
    Abstract: The present invention provides novel human PDE8 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE8 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE8 polypeptides.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: August 3, 1999
    Assignee: ICOS Corporation
    Inventor: Kate Loughney